200 related articles for article (PubMed ID: 3134383)
1. Focus on fenofibrate.
Brown WV
Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():31-40. PubMed ID: 3134383
[No Abstract] [Full Text] [Related]
2. A comparison of fenofibrate and clofibrate hypolipidemic effects.
Daubresse JC
Acta Clin Belg; 1980; 35(4):227-32. PubMed ID: 7015771
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Schneider A; Stange EF; Ditschuneit HH; Ditschuneit H
Atherosclerosis; 1985 Sep; 56(3):257-62. PubMed ID: 4052147
[TBL] [Abstract][Full Text] [Related]
5. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Smud R; Sermukslis B
Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
[TBL] [Abstract][Full Text] [Related]
6. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Brown WV
Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
[TBL] [Abstract][Full Text] [Related]
7. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Stohler R; Keller U; Riesen WF
Eur J Clin Pharmacol; 1989; 37(2):199-203. PubMed ID: 2507323
[TBL] [Abstract][Full Text] [Related]
8. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.
Farnier M; Dejager S
Am J Cardiol; 2000 Jan; 85(1):53-7. PubMed ID: 11078237
[TBL] [Abstract][Full Text] [Related]
9. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
[TBL] [Abstract][Full Text] [Related]
10. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
[No Abstract] [Full Text] [Related]
12. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Steinmetz J; Morin C; Panek E; Siest G; Drouin P
Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Tesone PA; Gladstein J; Acuña AM
Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
de Luis DA; Bachiller P; Aller R
Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
[No Abstract] [Full Text] [Related]
15. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
Wong MC; Wang HH; Liu KS
Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
[No Abstract] [Full Text] [Related]
16. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L
Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642
[No Abstract] [Full Text] [Related]
17. Choosing the right lipid-regulating agent. A guide to selection.
Farmer JA; Gotto AM
Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
[TBL] [Abstract][Full Text] [Related]
18. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Leiss O; Meyer-Krahmer K; von Bergmann K
J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
[TBL] [Abstract][Full Text] [Related]
19. Spectral-Domain OCT Imaging of Lipemia Retinalis.
Teoh CS; Yuen YS
Ophthalmol Retina; 2021 Oct; 5(10):1016. PubMed ID: 34579870
[No Abstract] [Full Text] [Related]
20. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
